Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.66 |
| ▸ | MMP2 | P08253 | 5/20 | 0.54 |
| ▸ | MMP13 | P45452 | 5/20 | 0.54 |
| ▸ | MMP1 | P03956 | 4/20 | 0.54 |
| ▸ | MMP3 | P08254 | 4/20 | 0.54 |
| ▸ | MMP7 | P09237 | 4/20 | 0.54 |
| ▸ | MMP9 | P14780 | 4/20 | 0.54 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026500 | 1.00 | CAPN1 (0.66) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL3913553 | 1.00 | CAPN1 (0.66) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL1907361 | 1.00 | CAPN1 (0.66) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL5363846 | 1.00 | CAPN1 (0.66) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL3917869 | 0.89 | CAPN1 (0.54) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL3905584 | 0.88 | MMP2 (0.54) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL3908110 | 0.84 | MMP13 (0.53) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL3906288 | 0.84 | MMP1 (0.60) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL3913036 | 0.83 | CAPN1 (0.48) | CAPN1MMP2MMP13MMP1MMP3 | |
| SCHEMBL19831386 | 0.83 | CAPN1 (0.48) | CAPN1MMP2MMP13MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572833-B2 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7052714-B1 | Ophthalmic adhesive preparations for percutaneous adsorption | SENJU PHARMACEUTICAL CO., LTD (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1334718-A1 | DRUG COMPOSITION COMPRISING DIPEPTYDYL ALDEHYDE DERIVATIVE | Senju Pharmaceutical Co., Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-0927716-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1221315-A1 | OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEOUS ABSORPTION | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | DPP4, DPP3, DPP7 | CAPN1 2707/4885MMP2 627/4885MMP13 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.